COVID-19 Pandemic


Current status of authorisations for combating COVID-19

Applications  received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

Empfehlung des Bundesrates: Bleiben Sie zu Hause, insbesondere, wenn Sie alt oder krank sind

Information on the current situation in Switzerland

Information for health professionnals, FAQs, recommendations for travellers.

 
Official information page
Covid-FAQ

FAQ on the COVID-19 vaccines

On this page you’ll find answers to frequently asked questions about mRNA vaccines.


All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?


Communication regarding COVID-19

22.09.2023

Swissmedic approves Pfizer coronavirus vaccine Comirnaty XBB.1.5

Comirnaty XBB.1.5 approved for persons aged 12 and over

30.08.2023

Authorisation application submitted for coronavirus vaccine Nuvaxovid XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5

21.08.2023

Clinical trials on medicinal products - Pandemic by SARS-CoV-2

Recommendations Swissmedic / swissethics for the treatment of patients

19.07.2023

Pfizer AG submits authorisation application for coronavirus vaccine Comirnaty XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5

13.07.2023

Moderna submits authorisation application for coronavirus vaccine Spikevax XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5

01.07.2023

Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3

11.04.2023

Swissmedic approves bivalent Pfizer Ltd. COVID-19 Original / Omicron BA 4-5 booster dose for adults aged 12 and over

Bivalent Original / Omicron BA.4-5 mRNA vaccine (tozinameran / famtozinameran) approved

27.03.2023

Comirnaty® COVID-10 vaccines from Pfizer AG: authorisation without special conditions approved

Three formulations (authorisation nos. 68225 and 68710, with 30 and 10 μg/dose) authorised for five years

08.03.2023

Swissmedic issues unlimited authorisation* for booster dose of Moderna's bivalent COVID-19 Original / Omicron BA.4-5 vaccine

Spikevax bivalent Original / Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over

24.02.2023

Reports of suspected adverse reactions to COVID-19 vaccines

16,855 reports of suspected adverse vaccination reactions evaluated
https://www.swissmedic.ch/content/swissmedic/en/home/news/coronavirus-covid-19.html